Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China

OBJECTIVE: This study assessed the long-term cost-effectiveness of saxagliptin+metformin (SAXA+MET) versus acarbose+metformin (ACAR+MET) in Chinese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on MET alone. METHODS: Systematic literature reviews were performed to identify st...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Shuyan, Zeng, Yuhang, Yu, Demin, Hu, Xiaoqian, Dong, Hengjin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119856/
https://www.ncbi.nlm.nih.gov/pubmed/27875596
http://dx.doi.org/10.1371/journal.pone.0167190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5119856/
https://www.ncbi.nlm.nih.gov/pubmed/27875596
http://dx.doi.org/10.1371/journal.pone.0167190

Ejemplares similares